Loading
A cheap gene test for DPYD, UGT1A1 and TPMT or NUDT15 before fluoropyrimidines, irinotecan or thiopurines identifies people at risk of severe or fatal toxicity so their dose can be lowered. The EMA has recommended DPD testing since 2020; US uptake remains partial.
Mandatory pre-treatment genotyping for DPYD variants before fluoropyrimidines, UGT1A1*28 and *6 before irinotecan, and TPMT/NUDT15 before thiopurines, with genotype-guided dose reduction per CPIC guidelines, reimbursed and built into chemotherapy order sets. The EMA recommended DPD testing in 2020 and a prospective Dutch study showed genotype-guided dosing reduced severe toxicity; US uptake remains partial.
Shares Wrong doses, Gastric & gastro-oesophageal junction cancer, Cytotoxic chemotherapy, Colorectal cancer.
Shares Chemotherapy roadmap: mustard gas → curative combinations → the warhead inside smarter drugs, Wrong doses, Toxicity and quality of life are undervalued, Cytotoxic chemotherapy.
Shares Wrong doses, Toxicity and quality of life are undervalued, Cytotoxic chemotherapy.
Shares Chemotherapy roadmap: mustard gas → curative combinations → the warhead inside smarter drugs, Wrong doses, Toxicity and quality of life are undervalued.
Shares Chemotherapy roadmap: mustard gas → curative combinations → the warhead inside smarter drugs, Toxicity and quality of life are undervalued.
Shares Wrong doses, Germline (hereditary) testing.
Shares Wrong doses, Toxicity and quality of life are undervalued.
Shares Wrong doses, Toxicity and quality of life are undervalued.